Dx & Vx Co., Ltd. (KOSDAQ:180400)

Market Cap	96.47B
Revenue (ttm)	31.12B
Net Income (ttm)	-51.44B
Shares Out	49.22M
EPS (ttm)	-1,132.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,555
Average Volume	142,698
Open	2,055.00
Previous Close	2,055.00
Day's Range	2,045.00 - 2,110.00
52-Week Range	1,309.00 - 2,890.00
Beta	-0.06
RSI	35.63
Earnings Date	Nov 14, 2025

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 88
• Stock Exchange: KOSDAQ
• Ticker Symbol: 180400

Financial Performance

In 2024, Dx & Vx's revenue was 33.95 billion, a decrease of -17.69% compared to the previous year's 41.24 billion. Losses were -47.03 billion, 71.1% more than in 2023.